Show simple item record

dc.contributor.authorLyke, Kirsten E
dc.contributor.authorAtmar, Robert L
dc.contributor.authorIslas, Clara Dominguez
dc.contributor.authorPosavad, Christine M
dc.contributor.authorSzydlo, Daniel
dc.contributor.authorPaul Chourdhury, Rahul
dc.contributor.authorDeming, Meagan E
dc.contributor.authorEaton, Amanda
dc.contributor.authorJackson, Lisa A
dc.contributor.authorBranche, Angela R
dc.contributor.authorEl Sahly, Hana M
dc.contributor.authorRostad, Christina A
dc.contributor.authorMartin, Judith M
dc.contributor.authorJohnston, Christine
dc.contributor.authorRupp, Richard E
dc.contributor.authorMulligan, Mark J
dc.contributor.authorBrady, Rebecca C
dc.contributor.authorFrenck, Robert W
dc.contributor.authorBäcker, Martín
dc.contributor.authorKottkamp, Angelica C
dc.contributor.authorBabu, Tara M
dc.contributor.authorRajakumar, Kumaravel
dc.contributor.authorEdupuganti, Srilatha
dc.contributor.authorDobrzynski, David
dc.contributor.authorColer, Rhea N
dc.contributor.authorArcher, Janet I
dc.contributor.authorCrandon, Sonja
dc.contributor.authorZemanek, Jillian A
dc.contributor.authorBrown, Elizabeth R
dc.contributor.authorNeuzil, Kathleen M
dc.contributor.authorStephens, David S
dc.contributor.authorPost, Diane J
dc.contributor.authorNayak, Seema U
dc.contributor.authorSuthar, Mehul S
dc.contributor.authorRoberts, Paul C
dc.contributor.authorBeigel, John H
dc.contributor.authorMontefiori, David C
dc.date.accessioned2022-07-11T15:34:57Z
dc.date.available2022-07-11T15:34:57Z
dc.date.issued2022-06-20
dc.identifier.urihttp://hdl.handle.net/10713/19349
dc.description.abstractctive immunity. We assess the magnitude and short-term durability of neutralizing antibodies after homologous and heterologous boosting with mRNA and Ad26.COV2.S vaccines. All prime-boost combinations substantially increase the neutralization titers to Omicron, although the boosted titers decline rapidly within 2 months from the peak response compared with boosted titers against the prototypic D614G variant. Boosted Omicron neutralization titers are substantially higher for homologous mRNA vaccine boosting, and for heterologous mRNA and Ad26.COV2.S vaccine boosting, compared with homologous Ad26.COV2.S boosting. Homologous mRNA vaccine boosting generates nearly equivalent neutralizing activity against Omicron sublineages BA.1, BA.2, and BA.3 but modestly reduced neutralizing activity against BA.2.12.1 and BA.4/BA.5 compared with BA.1. These results have implications for boosting requirements to protect against Omicron and future variants of SARS-CoV-2. This trial was conducted under ClincalTrials.gov: NCT04889209.en_US
dc.description.urihttps://doi.org/10.1016/j.xcrm.2022.100679en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofCell Reports. Medicineen_US
dc.rightsCopyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.en_US
dc.subjectBA.2.12.1en_US
dc.subjectBA.4/BA.5en_US
dc.subjectCOVID-19en_US
dc.subjectOmicron varianten_US
dc.subjectSARS-CoV-2en_US
dc.subjectboosteren_US
dc.subjectmRNA vaccineen_US
dc.subjectneutralizing antibodyen_US
dc.subjectrecombinant adenovirus vaccineen_US
dc.subjectsublineageen_US
dc.titleRapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.xcrm.2022.100679
dc.identifier.pmid35798000
dc.source.journaltitleCell reports. Medicine
dc.source.beginpage100679
dc.source.endpage
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record